Defeat Duchenne Canada Announce 2023-2024 Research Grants
Defeat Duchenne Canada, the country’s leader in Duchenne muscular dystrophy-funded research, is proud to announce that it will grant $880,320 toward five promising research projects this year – making the total awarded over its 29-year history $17.73M. The five new projects will enter a three-year agreement with the organization, joining six other research projects in years two and three of their funding.
Meet the researchers and hear the latest progress in Duchenne science.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.